- Home
- PFO vs ANTX Comparison
PFO vs ANTX Comparison
Compare PFO & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PFO | ANTX |
|---|---|---|
| Founded | 1991 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 123.3M | 135.4M |
| IPO Year | N/A | 2022 |
Fundamental Metrics
Financial Performance| Metric | PFO | ANTX |
|---|---|---|
| Price | $9.18 | $5.01 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $2.00 |
| AVG Volume (30 Days) | 29.4K | ★ 3.2M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 6.51% | N/A |
| EPS Growth | N/A | ★ 37.23 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.01 | $1.00 |
| 52 Week High | $9.90 | $6.91 |
Technical Indicators
Market Signals| Indicator | PFO | ANTX |
|---|---|---|
| Relative Strength Index (RSI) | 34.22 | 77.80 |
| Support Level | $9.16 | $1.05 |
| Resistance Level | $9.37 | $6.91 |
| Average True Range (ATR) | 0.10 | 0.78 |
| MACD | -0.02 | 0.31 |
| Stochastic Oscillator | 23.40 | 67.07 |
Price Performance
Historical ComparisonAbout PFO Flaherty & Crumrine Preferred and Income Opportunity Fund Incorporated
Flaherty & Crumrine Prfd Income Oppo is the United States-based diversified, closed-end management investment company. Its primary investment objective is to provide its common shareholders with high current income consistent with the preservation of capital. The fund invests in a diversified portfolio of preferred securities which includes traditional preferred stocks eligible for the inter-corporate dividends received a deduction and fully taxable preferred securities.
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology.